Table 5 Adjusted OR for duration of use of statins on survival determined by the nested case–control analysis.
| Duration (months) | Proportion of cases (n = 2266) | Proportion of controls (n = 9064) | OR* | 95% CI | p Value |
|---|---|---|---|---|---|
| No statins | 1821 (80.4%) | 6761 (74.6%) | 1.00 | ||
| 1–12 | 217 (9.6%) | 967 (10.7%) | 0.80 | 0.66 to 0.97 | 0.020 |
| 13–24 | 95 (4.2%) | 529 (5.8%) | 0.60 | 0.46 to 0.78 | <0.001 |
| 24–36 | 57 (2.5%) | 348 (3.8%) | 0.47 | 0.34 to 0.67 | <0.001 |
| 37–48 | 46 (2.0%) | 226 (2.5%) | 0.48 | 0.32 to 0.71 | <0.001 |
| 49–60 | 23 (1.0%) | 139 (1.5%) | 0.54 | 0.32 to 0.92 | 0.021 |
| >60 | 7 (0.3%) | 94 (1.0%) | 0.20 | 0.08 to 0.47 | <0.001 |
*OR adjusted for co‐morbidity (diabetes, hypertension, CCF, myocardial infarction, cancer), angiotensin converting enzyme inhibitors, aspirin, β blockers, calcium channel blockers, smoking, body mass index, and deprivation (Townsend score in fifths).